237 related articles for article (PubMed ID: 27527897)
1. Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.
He S; Gill BS; Heron DE; Kelley JL; Sukumvanich P; Olawaiye AB; Edwards RP; Comerci J; Beriwal S
Pract Radiat Oncol; 2017; 7(1):19-25. PubMed ID: 27527897
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy.
Chen CC; Wang L; Lu CH; Lin JC; Jan JS
J Formos Med Assoc; 2014 Dec; 113(12):949-55. PubMed ID: 24144528
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
[TBL] [Abstract][Full Text] [Related]
4. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
6. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
[TBL] [Abstract][Full Text] [Related]
7. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
8. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial.
Barillot I; Tavernier E; Peignaux K; Williaume D; Nickers P; Leblanc-Onfroy M; Lerouge D
Radiother Oncol; 2014 Apr; 111(1):138-43. PubMed ID: 24630537
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Chemotherapy and Vaginal Vault Brachytherapy With or Without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer.
Tétreault-Laflamme A; Nguyen-Huynh TV; Carrier JF; Samouëlian V; Sauthier P; Beauchemin MC; Barkati M
Int J Gynecol Cancer; 2016 Feb; 26(2):301-6. PubMed ID: 26745699
[TBL] [Abstract][Full Text] [Related]
10. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
[TBL] [Abstract][Full Text] [Related]
11. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
[TBL] [Abstract][Full Text] [Related]
12. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomised phase II trial evaluating adjuvant pelvic radiotherapy using either IMRT or 3-Dimensional planning for endometrial cancer.
Nugent K; Browne D; Dunne M; O Sullivan L; Shannon AM; Sharma D; Bradshaw S; McArdle O; Salib O; Lavan N; Gillham C
Acta Oncol; 2023 Aug; 62(8):907-914. PubMed ID: 37493622
[TBL] [Abstract][Full Text] [Related]
14. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
15. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy.
Lazzari R; Riva G; Augugliaro M; Vavassori A; Dicuonzo S; Cattani F; Comi S; Colombo N; Jereczek-Fossa BA
Int J Gynecol Cancer; 2020 May; 30(5):607-612. PubMed ID: 32188626
[TBL] [Abstract][Full Text] [Related]
16. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
17. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and toxicity of postoperative intensity-modulated versus three-dimensional conformal radiation therapy in patients with cervical cancer.
Lan ML; Yu X; Xiao H; Zhou P; Hu N; Li J; Wang G
Asia Pac J Clin Oncol; 2016 Dec; 12(4):430-436. PubMed ID: 26923341
[TBL] [Abstract][Full Text] [Related]
19. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
Viswanathan AN; Moughan J; Miller BE; Xiao Y; Jhingran A; Portelance L; Bosch WR; Matulonis UA; Horowitz NS; Mannel RS; Souhami L; Erickson BA; Winter KA; Small W; Gaffney DK
Cancer; 2015 Jul; 121(13):2156-63. PubMed ID: 25847373
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
